. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Nanomedicine. 2020 Jun 12;29:102236. doi: 10.1016/j.nano.2020.102236

Table 2:

PK parameters for α-CD99-A192

Parameter (Unit)	α-CD99-A192 IV (SD) (n=4)	95% Conf Interval [Lower to Upper bound]
Dose (nmol)^a	66.8 (2.8)	[62.4 to 71.2]
CL (ml/hr)^a	0.28 (0.02)	[0.24 to 0.32]
AUC (μM*hr)^a	240 (17)	[212 to 268]
AUMC (μM*hr²)^a	5130 (959)	[3610 to 6660]
MRT (hr)^a	21.3 (2.6)	[17.1 to 25.4]
V_ss (mL)^a	5.92 (0.63)	[4.91 to 6.92]
C₀ (μM)^b	42.6 (26.3)	[0.8 to 84.5]
A (μM)^b	32.5 (25.2)	[0 to 72.5]
B (μM)^b	10.2 (1.2)	[8.3 to 12.0]
α (hr⁻¹)^b	6.13 (5.88)	[0 to 15.5]
β (hr⁻¹)^b	0.044 (0.004)	[0.037 to 0.051]
t_1/2α (hr)^b	0.24 (0.20)	[0 to 0.56]
t_1/2β (hr)^b	15.8 (1.4)	[13.5 to 18.1]
k_elimination (hr⁻¹)^b	0.17 (0.08)	[0.04 to 0.30]
k_{plasma→tissue} (hr⁻¹)^b	4.61 (5.09)	[0 to 12.7]
k_{tissue→plasma} (hr⁻¹)^b	1.39 (0.90)	[0 to 2.82]
AUC (μmol*h)^b	239 (36)	[182 to 296]
CL (ml/h)^b	0.28 (0.04)	[0.22 to 0.35]
V_d^a (ml)^b	1.92 (0.77)	[0.69 to 3.15]

determined using non-compartmental analysis

determined by fitting to Eq. 5 and fit to a two-compartment model of an intravenous bolus³⁴